Mill Creek Life Sciences' news page features news, events, and press releases, including a December 10, 2019 announcement of Avobis Bio, a joint venture between Mayo Clinic and W. L. Gore & Associates for regenerative therapies.
Mill Creek Life Sciences says its team focuses on innovation, quality, and customer needs. The company is growing and is an equal opportunity employer.
Mill Creek Life Sciences provides tools and technologies to support the development and application of cellular and biologic therapeutics. Its technology was licensed from discoveries at the Mayo Clinic.
The page provides a contact form for inquiries and lists Mill Creek Life Sciences, Inc.'s address as 221 1st Avenue SW, Suite 209, Rochester, MN 55902, USA.
The company's human platelet lysates are derived from human platelets and have been used to grow cells for thousands of patients globally in more than 50 Phase I, II, and III clinical trials for more than a decade.
Mill Creek Life Sciences, Inc.'s privacy policy, effective November 19, 2025, describes how the company collects, processes, and retains information and states its commitment to protecting privacy.